Milanese C, La Mantia L, Salmaggi A, Eoli M
Istituto Nazionale Neurologico C. Besta, Milan, Italy.
J Neurol. 1993 May;240(5):295-8. doi: 10.1007/BF00838165.
Forty patients, affected by multiple sclerosis with remitting-relapsing or progressive course, were included in a double blind study of treatment with azathioprine (2 mg/kg/day) lasting 3 years. The mean changes on the Expanded Disability Status Scale and in the survival analysis show a trend in favour of azathioprine both in slowing disease progression and reducing relapse frequency. These findings, repeatedly observed in similar trials, indicate that azathioprine should be used in the treatment of multiple sclerosis.
40例复发缓解型或进展型多发性硬化患者被纳入一项为期3年的硫唑嘌呤（2毫克/千克/天）治疗双盲研究。扩展残疾状态量表的平均变化及生存分析表明，硫唑嘌呤在减缓疾病进展和降低复发频率方面均有优势。这些在类似试验中反复观察到的结果表明，硫唑嘌呤应用于多发性硬化的治疗。
